

Phylogenetic Grouping and Antimicrobial Resistance Profiles of *Escherichia coli* Isolated from Calves in Xinjiang, China

Xingxing ZHANG ^{1,2,a,†} Jie LI ^{1,b,†} Ling ZHANG ^{3,c} Jun QIAO ^{1,2,d} Qingling MENG ^{1,2,e} Ying CHEN ^{4,f}
Kuojun CAI ^{5,g} Xin HUANG ^{2,h} Tongzhong WU ^{2,i} Mengli HAN ^{2,j} Fagang ZHONG ^{2,k}

[†] These authors contributed equally to this work

¹ College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, 832003, CHINA

² State Key Laboratory for Sheep Genetic Improvement and Healthy Production, Xinjiang Academy of Agricultural and Reclamation Science, Shihezi, Xinjiang, 832000, CHINA

³ College of Animal Science and Technology, Tarim University, Alar, Xinjiang, 843300, CHINA

⁴ College of Animal Science and Technology, Xinjiang Agricultural Vocational and Technical College, Changji, Xinjiang, 31100, CHINA

⁵ Urumqi Animal Disease Control and Diagnosis Center, Urumqi, Xinjiang, 830063, CHINA

^a ORCID: 0000-0002-9838-6962; ^b ORCID: 0000-0002-7519-2348; ^c ORCID: 0000-0002-2215-8955; ^d ORCID: 0000-0001-5210-4379

^e ORCID: 0000-0002-1190-0114; ^f ORCID: 0000-0001-8131-3241; ^g ORCID: 0000-0002-1927-2677; ^h ORCID: 0000-0002-8966-3497

ⁱ ORCID: 0000-0003-3280-5869; ^j ORCID: 0000-0003-3103-728X; ^k ORCID: 0000-0003-0424-3037

Article ID: KVFD-2019-23046 Received: 26.07.2019 Accepted: 15.12.2019 Published Online: 15.12.2019

How to Cite This Article

Zhang Z, Li J, Zhang L, Qiao J, Meng Q, Chen Y, Cai K, Huang X, Wu T, Han M, Zhong F: Phylogenetic grouping and antimicrobial resistance profiles of *Escherichia coli* isolated from calves in Xinjiang, China. *Kafkas Univ Vet Fak Derg*, 26 (3): 329-335, 2020. DOI: 10.9775/kvfd.2019.23046

Abstract

The widespread multidrug-resistant *Escherichia coli* strains have caused a severe challenge to animal health and the development of breeding industries. The purpose of this study was to investigate the phylogenetic grouping and antimicrobial resistance profiles of *E. coli* isolated from diarrheic calves in Xinjiang province, China. In this study, a total of 379 *E. coli* strains were isolated from 379 rectal swab samples of diarrheic calves. They were further analyzed their phylogenetic groupings by multiplex PCR, and were clustered into four phylogenetic groups, A (36.1%), B1 (17.4%), B2 (15.6%), and D (30.9%). All *E. coli* isolates were tested for their susceptibility to 15 antimicrobial agents by Kirby-Bauer (KB) method. The isolates showed the highest resistance rates against ampicillin (64.9%), followed by streptomycin (59.4%), tetracycline (53.8%), sulfamethoxazole/trimethoprim (50.9%), chloramphenicol (45.6%), kanamycin (44.1%) and enrofloxacin (42.0%). *E. coli* isolates exhibited lower resistance to ceftazidime (15.0%) and polymyxin (12.6%). The resistance genes *bla*_{TEM}, *bla*_{OXA}, *mcr-1*, *strA-strB*, *aadA*, *tet(A)*, *tet(B)*, and *tet(C)* were detected in 68.3% (168/246), 27.2% (67/246), 14.6% (7/48), 51.1% (115/225), 24.9% (56/225), 51.5% (105/204), 44.6% (91/204), and 7.8% (16/204) of *E. coli* isolates, respectively. These results demonstrate that prevalent multi-drug resistance and high level of antimicrobial resistance genes exist among *E. coli* from Xinjiang diarrheic calves and pose a potential public health concern.

Keywords: *Escherichia coli*, Phylogenetic grouping, Antimicrobial resistance, Resistance genes, Calf

Çin'in Sincan Bölgesindeki Buzağılardan İzole Edilen *Escherichia coli*'nin Filogenetik Gruplandırması ve Antimikrobiyal Direnç Profili

Öz

Yaygın çoklu ilaç dirençli *Escherichia coli* suşları, hayvan sağlığı ve üretim endüstrilerinin gelişimi için ciddi bir zorluk yaratmaktadır. Bu çalışmanın amacı, Çin'in Xinjiang eyaletindeki ishalleri buzağılardan izole edilen *E. coli*'nin filogenetik gruplandırma ve antimikrobiyal direnç profilini araştırmaktır. Çalışmada, 379 adet ishalleri buzağıdan alınan rektal sıvab örneğinden toplam 379 *E. coli* suşu izole edildi. Filogenetik gruplar ayrıca çoklu PCR ile analiz edildi ve A (%36.1), B1 (%17.4), B2 (%15.6) ve D (%30.9) olarak dört gruba kümelendi. Tüm *E. coli* izolatları, Kirby-Bauer (KB) yöntemiyle 15 antimikrobiyal maddeye karşı duyarlılıkları açısından test edildi. İzolatlar ampisiline karşı en yüksek direnç oranını gösterirken (%64.9), bunu streptomisin (%59.4), tetrasiklin (%53.8), sülfametoksazol/trimetoprim (%50.9), kloramfenikol (%45.6), kanamisin (%44.1) ve enrofloksasin (%42.0) izledi. *E. coli* izolatları seftazidime (%15.0) ve polimiksine (%12.6) daha düşük direnç gösterdi. *E. coli* izolatlarında direnç genleri *bla*_{TEM}, *bla*_{OXA}, *mcr-1*, *strA-strB*, *aadA*, *tet(A)*, *tet(B)* ve *tet(C)* sırasıyla %68.3 (168/246), %27.2 (67/246), %14.6 (7/48), %51.1 (115/225), %24.9 (56/225), %51.5 (105/204), %44.6 (91/204) ve %7.8 (16/204) olarak belirlendi. Bu sonuçlar, Xinjiang bölgesindeki ishalleri buzağılardan elde edilen *E. coli* suşlarında yaygın çoklu ilaç direnci ve yüksek düzeyde antimikrobiyal direnç genlerinin bulunduğunu ve potansiyel bir halk sağlığı sorunu teşkil ettiğini gösterdi.

Anahtar sözcükler: *Escherichia coli*, Filogenetik gruplama, Antimikrobiyal direnç, Direnç genleri, Buzağı



İletişim (Correspondence)



+86-993-2055036 (J.Qiao), +86-993-6683697 (F. Zhong), Fax: +86-993-2055036



qj710625@163.com (J.Qiao), zfg125@sohu.com (F. Zhong)

INTRODUCTION

Antimicrobial resistance is a serious threat to both animal breeding and human health [1]. It is estimated that more than 50% of the world's antibacterials are used in husbandry industry [2], and among them, nearly 90% of antibacterial agents have been used for prophylaxis or growth promotion [3]. Due to the long-term misuse of antibiotics in economically important animals, bacterial resistance to drugs has become an increasingly severe issue [4,5] as increased incidence of antibiotic-resistant infections coupled with a declining antibiotic pipeline is creating a global public health threat [1,6].

Escherichia coli is the most common type of abundant bacteria in human and animal intestines. Some serotypes are pathogenic and can cause diarrhea, meningitis, urinary tract infections, sepsis, or pneumonia in humans and animals [7,8]. Due to the extensive use of antibiotics in veterinary clinics, it is easy for *E. coli* to evolve resistance to drugs and become a reservoir for antibiotic resistance and resistance genes [9,10]. In recent years, numerous studies have been reported on the drug resistance of *E. coli* in cattle, including resistance phenotypes and genotypes, and also the impact of antibiotics on the selection of resistance genes [11-14]. Furthermore, drug-resistant *E. coli* isolates may not only threaten veterinary clinical treatment of infections, but also possibly spread to human via the food chain, thus posing a challenge to public health [15,16].

The Xinjiang Uygur Autonomous Region, with 1.66 million km², is situated in northwestern China and borders Russia, Kazakhstan, and other Central Asian countries. This region is one of the major pastoral areas in China with well-developed animal husbandry industry and an estimated cattle population of 4.2 million (Xinjiang Statistical Yearbook, 2016, C832.45-54). Therefore, the aim of this study was to clarify the phylogenetic grouping, antimicrobial resistance profiles and resistance genes of *E. coli* isolates collected from calves in Xinjiang.

MATERIAL and METHODS

Ethics Statement

This study was carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals of the Scientific Research Department of Xinjiang Academy of Agricultural and Reclamation Sciences (protocol approval number: XJNKXY-AEP-038). This study did not involve any endangered or protected animal species. Individual oral/written informed consent for the use of samples was obtained from all the animal owners.

Sample Sources and Antimicrobial Use Histories

From May 2016 to May 2017, a total of 379 rectal swab samples were collected from 1 to 6-month-old diarrheic

calves in six large-scale dairy farms and one cattle farm located in different districts (Urumqi, Wujiaqu, Changji, Shihezi, Kuitun) in Xinjiang, China, along with geographic and cattle industry representatives. The most commonly used drugs for calves in these cattle farms were: ampicillin, streptomycin, tetracycline and sulfonamides.

Isolation and Identification of *E. coli* Strains

After adding 2 mL of 0.85% saline to the collection tubes, the rectal swab samples were vortexed for 10 min at room temperature and allowed to stand for 5 min, according to a previously reported protocol with minor modifications [17]. Next, 10 µL supernatant was taken and inoculated on MacConkey agar (Difco Laboratories, Detroit, MI, USA) for overnight culturing at 37°C. One colony per sample was selected for pure culturing. The suspected *E. coli* colonies were first identified by biochemical tests (Tianhe, Hangzhou, China), and they were further confirmed based on the VITEK 2 Automatic microbial analysis system (VITEK® 2 Compact 30) and 16S rRNA PCR and sequencing (Table 1). The confirmed *E. coli* isolates were selected for further investigation.

Phylogenetic Grouping of *E. coli* Isolates

The isolated *E. coli* was identified and grouped using the triple PCR method [18]. The groups were determined based on the presence or absence of *chuA* and *yjaA* genes, as well as an unknown DNA fragment (TspE4.C2). Primers (Table 1) used in this assay were synthesized by Beijing Genomics Institute (BGI). PCR products were analyzed by 1% agarose gel electrophoresis and recorded by a gel imaging system and the amplicons were sequenced.

Drug Susceptibility Test

The drug susceptibility test was conducted following the Kirby-Bauer (KB) method recommended by the Clinical and Laboratory Standards Institute [19]. The bacteria were collected with a sterile loop, suspended in peptone water, and incubated at 37°C for 2 h. The turbidity of the suspension was adjusted to 0.5 McFarland's standard (1.5×10⁸ CFU/mL). The suspension was then spread onto the surface of a cation-adjusted Mueller-Hinton agar (MHA) (AOBOX, Beijing, China) plate using sterile cotton swabs. The following 15 antimicrobial agents (Oxoid, Basingstoke, England) were included in the assay: ampicillin (AMP) (10 µg), cephalixin (LEX) (30 µg), cefotaxime (CTX) (30 µg), ceftazidime (CAZ) (30 µg), streptomycin (STR) (10 µg), gentamicin (GEN) (10 µg), kanamycin (KAN) (30 µg), amikacin (AMI) (30 µg), tetracycline (TET) (30 µg), doxycycline (DOX) (30 µg), chloramphenicol (CHL) (30 µg), polymyxin B (POL) (300 IU), norfloxacin (NOR) (10 µg), enrofloxacin (EN) (10 µg), and sulfamethoxazole/trimethoprim (SXT) (23.75/1.25 µg). Test results were interpreted based on the criteria recommended by the M100, 28th edition of the CLSI (Wayne, PA, United States) (Clinical Laboratory Standards Institute) [19]. The *E. coli* strain ATCC 25922 was used for quality control.

Table 1. The oligonucleotide sequence and predicted sizes used in the PCR

Primer Name	Primer Sequence (5'-3')	Target Gene	Size (bp)	Reference
16S-F	GCGGACGGGTGAGTAATGT	16S rRNA	200	This study
16S-R	TCATCCTCTCAGACCAGCTA			
ChuA-F	GACGAACCAACGGTCAGGAT	chuA	279	[17]
ChuA-R	TGCCGCCAGTACCAAAGACA			
YjaA-F	TGAAGTGTGAGGAGACGCTG	yjaA	211	[17]
YjaA-R	ATGGAGAATGCGTTCCTCAAC			
TspE4C2-F	GAGTAATGTCGGGGCATTCA	TSPE4.C2	152	[17]
TspE4C2-R	CGCGCCAACAAAGTATTACG			
bla(TEM)-F	TTGGGTGCACGACTGGGT	bla _{TEM}	503	[12]
bla(TEM)-R	TAATTGTTGCCGGGAAGC			
bla(PSE)-F	CGCTTCGGGTTAACAAGTAC	bla _{PSE}	419	[12]
bla(PSE)-R	CTGGTTCATTTCAGATAGCG			
bla(OXA)-F	AGCAGCGCCAGTGCATCA	bla _{OXA}	708	[12]
bla(OXA)-R	ATTGACCCCAAGTTTCC			
mcr-1-F	CGGTCAGTCCGTTTGTTC	mcr-1	309	[19]
mcr-1-R	CTTGGTCGGTCTGTAGGG			
tet(A)-F	GCTACATCTGCTTGCTTC	tet(A)	210	[20]
tet(A)-R	CATAGATCGCCGTGAAGAGG			
tet(B)-F	TTGGTTAGGGGCAAGTTTTG	tet(B)	659	[20]
tet(B)-R	GTAATGGGCAATAACACCG			
tet(C)-F	CTTGAGAGCCTTCAACCCAG	tet(C)	418	[20]
tet(C)-R	ATGGTCGTCATCTACCTGCC			
strA-strB-F	TATCTGCGATTGGACCCTCTG	strA-strB	538	[21]
strA-strB-R	CATTGCTCATCATTTGATCGGCT			
AadA-F	GCAGCGCAATGACATTCTTG	aadA1 or aadA2	282	[22]
AadA-R	ATCCTCGGCGGATTTTG			

Detection of Resistance Genes by PCR Assay

Bacterial genomic DNA was extracted according to the genome DNA extraction kit manufacturer's instructions (OMEGA Bio-tek Inc., Norcross, GA, USA), and was used as template for PCR analysis. For ampicillin-resistant *E. coli*, triple PCR was used to detect three β -lactam-resistant genes: bla_{TEM}, bla_{OXA}, and bla_{PSE} [12]. For polymyxin-resistant *E. coli*, mcr-1 was detected by PCR [20]. For tetracycline-resistant *E. coli*, multiplex PCR was used to detect three tetracycline-resistant genes, tet(A), tet(B), and tet(C) [21]. For streptomycin-resistant *E. coli*, duplex PCR was used to test two aminoglycoside-resistant genes: strA-strB and aadA [22,23]. The target gene amplified by PCR was ligated with vector pMD19-T (TaKaRa, Dalian, China) and transformed into *E. coli* DH5 α competent cells, and the recombinant plasmid was sequenced (TaKaRa, Dalian, China).

Statistical Analysis

Epi Info version 7.2 (CDC) was used to perform statistical analysis. Comparison of drug resistant differences in the four phylogenetic groups (A, B1, B2, D) of *E. coli* was conducted by the χ^2 -test. $P < 0.05$ was considered statistically significant.

RESULTS

E. coli Isolation and Phylogenetic Characterization

A total of 379 *E. coli* strains (100% isolation rate) were isolated from calve rectal swab samples. Isolated strains were further identified and grouped by checking their PCR products with gel electrophoresis. There were three specific bands observed, 279 bp, 211 bp and (or) 152 bp, corresponding to chuA, yjaA and the DNA fragment TspE4.C2. These strains were distributed differently among the four phylogenetic groups (Table 2) by comparing PCR bands with the positive strains (Fig. 1). group A, B1, B2 and D accounted for 36.1% (137/379), 17.4% (66/379), 15.6% (59/379) and 30.9% (117/379).

Table 2. Phylogenetic clustering of *E. coli* isolated from calves

Phylogenetic Group(s)	No. of Isolates (%) by Origin
A	137 (36.1)
B1	66 (17.4)
B2	59 (15.6)
D	117 (30.9)





Fig 1. Phylogenetic grouping for *E. coli* isolates based on Triplex PCR method. Each combination of *chuA* and *yjaA* gene and DNA fragment TSPE4.C2 amplification allowed phylogenetic grouping of a strain. Lane M, contained markers. Lane 1 and 2, group A [(*chuA*⁻, *yjaA*⁻, TspE4.C2⁻) and (*yjaA*⁺, *chuA*⁻, TspE4.C2⁻)]; lane 3, group B1 [(*chuA*⁻, *yjaA*, TspE4.C2⁺)]; lanes 6 and 7, group B2 [(*chuA*⁺, *yjaA*⁺, TspE4.C2⁻) and (*chuA*⁺, *yjaA*⁺, TspE4.C2⁺)]; lane 4 and 5, group D [(*chuA*⁺, *yjaA*⁻, TspE4.C2⁻) and (*chuA*⁺, *yjaA*⁻, TspE4.C2⁺)]

Fig 2. The antimicrobial resistance of *E. coli* isolates. AMP: Ampicillin, LEX: Cephalexin, CTX: Cefotaxime, CAZ: Ceftazidime, STR: Streptomycin, GEN: Gentamicin, KAN: Kanamycin, AMI: Amikacin, TET: Tetracycline, DOX: Doxycycline, CHL: Chloramphenicol, POL: Polymyxin B, NOR: Norfloxacin, EN: Enrofloxacin, SXT: Sulfamethoxazole/Trimethoprim



Antimicrobial Susceptibility

Of the 379 *E. coli* strains, 64.9% (246/379) were resistant to ampicillin, which was the highest rate from the 15 antibiotics tested, followed by streptomycin (59.4%), tetracycline (53.8%), sulfamethoxazole/trimethoprim (50.9%), Chloramphenicol (45.6%), Kanamycin (44.1%), Enrofloxacin (42.0%), Gentamicin (35.4%) and Norfloxacin (34.85%). Additionally, 29.8%, 23.8%, 21.4%, 21.4%, 15.0%, and 12.6% *E. coli* isolates exhibited resistance to cephalexin, doxycycline, amikacin, cefotaxime, ceftazidime, and polymyxin B, respectively (Fig. 2, Table 3).

The *E. coli* from different phylogenetic groups showed different resistance to the 15 different kinds of antibiotics. Groups A and D had relatively higher resistance rates, and group B2 showed the most susceptibility to antibiotics (Table 3).

Resistance Gene Profiles from Different Resistance Phenotype of *E. coli* Strains

Most of the 379 *E. coli* strains had different resistance genotypes (Fig. 3, Table 4). Among ampicillin-resistant strains, 91.5% (225/246) carried either *bla*_{TEM} or *bla*_{OXA} gene, or both and. no *bla*_{PSE} gene was detected. Among tetracycline-resistant strains, 94.1% (192/204) had one or two of the genes *tet*(A), *tet*(B) and *tet*(C). Among streptomycin-resistant strains, 70.2% (158/225) carried

the *strA-strB* or *aadA* gene, or both. Among polymyxin-resistant strains, 14.6% (7/48) had the *mcr-1* gene.

DISCUSSION

In recent years, with the development of a large-scale cattle industry in China, the incidence of cattle diseases has continued to rise, it turns to be an essential issue to understand the antibiotic resistance situation among cattles in order to provide better anti-bacterial therapy and rational use of antibiotics. Antibiotics are extensively used in animal husbandry to prevent common bacterial diseases or promote livestock growth. The antimicrobial resistance has emerged as a serious threat to both the cattle industry and public health [24]. In our study, 64.9% of *E. coli* isolates were resistant to ampicillin, and more than 50% of isolates showed resistance against streptomycin, tetracycline and sulfamethoxazole/trimethoprim. Coincidentally, these four antimicrobial agents were widely used in the local cattle farm, suggesting that antimicrobial agents used in cattle have driven the emergence and abundance of resistance.

In the United States, among *E. coli* strains taken from cattle, resistance rates have been shown to be 23.7% for tetracycline, 10.5% for sulfamethoxazole/trimethoprim, and 9.5% for streptomycin [25]. In Germany, drug resistance rates of *E. coli* from calves were 65.9% for tetracycline, 59.0% for amoxicillin, 56.5% for sulfamethoxazole/trimethoprim, and

Table 3. Antimicrobial sensitivity of different phylogenetic groups of *E. coli* isolates

Classes	Antibacterial Agents	Number of Resistant Isolates (Percentage of Resistance %)				
		A (n=137)	B1 (n=66)	B2 (n=59)	D (n=117)	Total (n=379)
Beta-lactams	<i>Ampicillin</i>	84 (61.3 %)	39 (59.1%)	32 (54.2%)	91 (77.8%)	246 (64.9)
	<i>Cephalexin</i>	37 (27.0%)	18 (27.7%)	16 (27.1%)	42 (35.9%)	113 (29.8)
	<i>Cefotaxime</i>	29 (21.2%)	13 (19.7%)	12 (20.3%)	27 (23.0%)	81 (21.4)
	<i>Ceftazidime</i>	20 (14.6%)	8 (12.1%)	7 (11.8%)	22 (18.8%)	57 (15.0)
Aminoglycosides	<i>Streptomycin</i>	79 (57.6%)	36 (54.5%)	29 (49.2%)	81 (69.2%)	225 (59.4)
	<i>Gentamicin</i>	44 (32.1%)	20 (30.3%)	18 (30.5%)	52 (44.4%)	134 (35.4)
	<i>Kanamycin</i>	55 (40.2%)	29 (43.9%)	18 (30.5%)	65 (55.6%)	167 (44.1)
	<i>Amikacin</i>	30 (21.9%)	12 (18.2%)	11 (18.6%)	28 (23.9%)	81 (21.4)
Tetracyclines	<i>Tetracycline</i>	67 (48.9%)	35 (53.0%)	32 (54.2%)	70 (59.8%)	204 (53.8)
	<i>Doxycycline</i>	29 (21.2%)	13 (19.7%)	12 (20.3%)	36 (30.7%)	90 (23.7)
Phenicols	<i>Chloramphenicol</i>	58 (42.3%)	25 (37.9%)	21 (35.6%)	69 (58.9%)	173 (45.6)
Polypeptides	<i>Polymyxin B</i>	15 (10.1%)	8 (12.1%)	4 (6.7%)	21 (17.9%)	48(12.6)
Quinolones	<i>Norfloxacin</i>	42 (30.7%)	22 (33.3%)	16 (27.1%)	52 (44.4%)	132 (34.8)
	<i>Enrofloxacin</i>	51 (37.2%)	27 (40.9%)	20(33.9%)	61 (52.1%)	159 (42.0)
Sulfonamides	<i>Sulfamethoxazole/Trimethoprim</i>	66 (48.1%)	32 (48.5%)	21 (35.6%)	74 (63.2%)	193 (50.9)

Table 4. Detection of resistance genes from different resistance phenotypes of clinical isolates of *Escherichia coli*

Phenotype	Resistance Gene	No. of Isolates (%)
Ampicillin (n=246)	<i>bla_{TEM}</i>	158 (64.2)
	<i>bla_{OXA}</i>	57 (23.2)
	<i>bla_{TEM}</i> & <i>bla_{OXA}</i>	10 (4.1)
	No gene detected	21 (8.5)
Tetracycline (n=204)	<i>tet(A)</i>	85(41.7)
	<i>tet(B)</i>	74 (36.3)
	<i>tet(C)</i>	13(6.4)
	<i>tet(A)+tet(B)</i>	17 (8.3)
	<i>tet(A)+tet(C)</i>	3 (1.5)
	No gene detected	12 (5.9)
Streptomycin (n=225)	<i>strA-strB</i>	102 (45.3)
	<i>aadA</i>	43 (19.1)
	<i>strA-strB+aadA</i>	13 (5.8)
	No gene detected	67 (29.8)
Polymyxin B (n=48)	<i>mcr-1</i>	7 (14.6 %)
	No gene detected	41 (85.4 %)

52.4% for streptomycin [13]. In France, the drug resistance rates of *E. coli* from calves was 79.8% for tetracycline, 68.0% for sulfa drugs, 61.0% for amoxicillin, and 60.1% for streptomycin [14]. The overall rates of drug-resistant *E. coli* in this study were higher than those in the United States but lower than them of Germany and France [13,14,25].

In this study, *E. coli* isolates were divided into four phylogenetic groups, A (36.1%), B1 (17.4%), B2 (15.6%) and D (30.9%). It has been reported that B2 and D are highly

pathogenic groups [18,26], and different hosts from different regions carry distinct *E. coli* groups [27,28]. Rodriguez et al. [29] found that more group A (38%) and D (28.1%) and less group B2 (18.5%) were identified among 524 avian pathogenic *E. coli* isolates from the United States. Tetsuo Asai et al. [30] demonstrated that group B2 *E. coli* from chickens only appeared in isolates from diseased chickens. Studies in Brazil and Japan showed that healthy cattle and pigs carried more groups A and B1 *E. coli* while no group B2 [26]. Extensive antibiotic use can lead to antibiotic pressure on bacterial evolution in that niche, and selection will be directed toward to success of the most resistant pathogens [31]; Simultaneously, during colonization and infection, the most virulent pathogens will be the most successful and will therefore be the most likely to survive. Our results showed that the highly pathogenic groups D were more severely resistant than symbiotic strains and low pathogenic groups (Table 3) suggesting that their resistance might be related to their pathogenicity.

The resistance genes are usually located on chromosomes and mobile genetic elements [32,33], and the transference of these mobile genetic elements is an important reason for increasing numbers of multi-drug-resistant bacteria [34,35]. Among 9 genes we analyzed, our samples showed positive to *bla_{TEM}*, *bla_{OXA}*, while negative to *bla_{PSE}*. As comparison, *bla_{TEM}* and *bla_{PSE}* instead of *bla_{OXA}* were detected in *E. coli* from Canadian calves [36]. The detection rate of the *mcr-1* gene was 14.6% in this study, which is higher than that of Belgian bovine *E. coli* (11.5%) [37], but lower than that of French bovine *E. coli* (20.5%) [38]. The tetracycline resistance was mainly encoded by *tet(A)* and *tet(B)* genes, wherein *tet(A)* (51.5%) had higher prevalence than *tet(B)* (46.1%); this result is similar to the studies by Guerra et al. [12] and Van




Fig 3. PCR detection of antimicrobial resistance genes in *E. coli* isolates from calves. **A:** PCR amplification of *tet(A)*, *tet(B)* and *tet(C)* genes; 1-6: *tet(A)* (210 bp), *tet(B)* (659 bp) and *tet(C)* (418 bp); 7: Control negative; M: DNA Marker DL-2000; **B:** PCR amplification of *bla*_{TEM1}, *bla*_{PSE1} and *bla*_{OXA1} genes; 1-7: *bla*_{TEM1} (503 bp) and *bla*_{OXA1} (708 bp); 8: Control negative; M: DNA Marker DL-2000; **C:** PCR amplification of *strA-strB* and *aadA* genes; 1-6: *strA-strB* (538 bp) and *aadA* (282 bp); 7: Control negative; M: DNA Marker DL-2000; **D:** PCR amplification of *mcr-1* gene; 1-4: *mcr-1* (309 bp); 5: Control negative; M: DNA Marker DL-2000

et al.^[39]. Additionally, in streptomycin-resistant *E. coli*, the *strA-strB* gene was the most common detected resistance determinant, which is consistent with previous studies^[22].

In conclusion, antimicrobial resistance profiles and phylogenetic grouping of the *E. coli* clinical strains isolated from Xinjiang calves were clarified. The antibiotic resistance rates were high in diarrheal calves in Xinjiang. Therefore, the possibility of transmission of *E. coli* from calves to humans, particularly those in highly pathogenic group, can not be excluded. Also, further studies are needed to elucidate the risk of transmission to humans by analyzing the clonal relationship in *E. coli* from calves and humans.

ACKNOWLEDGEMENTS

We thank the field staff who provided the technical assistance for this study. This work was supported by the plan of youth innovation leader in science and technology of XPCC (2016BC014), International Science & Technology Cooperation Program of China (2014DFR31310), National Natural Science Foundation of China (31360596, 31460654), Outstanding young and middle-aged talents Training Project of State Key Laboratory for Sheep Genetic Improvement and Healthy Production (SKLSGIHP2017A03), Science and Technology Planning Project of XPCC (2017BA038, 2019BC004).

CONFLICT OF INTERESTS STATEMENT

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

1. Kishony R, Collins JJ: Editorial overview: Antimicrobials: Grappling with the complexities of antibiotics and resistance. *Curr Opin Microbiol*, 21, v-vi, 2014. DOI: 10.1016/j.mib.2014.10.004
2. Krishnasamy V, Otte J, Silbergeld E: Antimicrobial use in Chinese

swine and broiler poultry production. *Antimicrob Resist Infect Control*, 4:17, 2015. DOI: 10.1186/s13756-015-0050-y

3. Merle R, Hajek P, Käsbohrer A, Hegger-Gravenhorst C, Mollenhauer Y, Robanus M, Ungemach FR, Kreienbrock L: Monitoring of antibiotic consumption in livestock: A German feasibility study. *Prev Vet Med*, 104 (1-2): 34-43, 2012. DOI: 10.1016/j.prevetmed.2011.10.013

4. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ: Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. *Clin Microbiol Rev*, 26 (2): 289-307, 2013. DOI: 10.1128/CMR.00001-13

5. Ghodousi A, Bonura C, Di Noto AM, Mammina C: Extended-spectrum β -Lactamase, AmpC-producing, and fluoroquinolone-resistant *Escherichia coli* in retail broiler chicken meat, Italy. *Foodborne Pathog Dis*, 12 (7): 619-625, 2015. DOI: 10.1089/fpd.2015.1936

6. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI: Tackling antibiotic resistance. *Nat Rev Microbiol*, 9 (12): 894-896, 2011. DOI: 10.1038/nrmicro2693

7. Bert F, Johnson JR, Ouattara B, Leflon-Guibout V, Johnston B, Marcon E, Valla D, Moreau R, Nicolas-Chanoine MH: Genetic diversity and virulence profiles of *Escherichia coli* isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. *J Clin Microbiol*, 48 (8): 2709-2714, 2010. DOI: 10.1128/JCM.00516-10

8. Aslantaş Ö, Elmacioğlu S, Yılmaz EŞ: Prevalence and characterization of ESBL- and AmpC-producing *Escherichia coli* from cattle. *Kafkas Univ Vet Fak Derg*, 23, 63-67, 2017. DOI: 10.9775/kvfd.2016.15832

9. Sakin F, Mújde C, Aslantaş Ö: Isolation and molecular characterization of extended spectrum beta-lactamase (ESBL) producing *Escherichia coli* from cage birds in Adana region, Turkey. *Kafkas Univ Vet Fak Derg*, 24 (4): 613-617, 2018. DOI: 10.9775/kvfd.2018.19731

10. Lay KK, Koowattananukul C, Chansong N, Chuanchuen R: Antimicrobial resistance, virulence, and phylogenetic characteristics of *Escherichia coli* isolates from clinically healthy swine. *Foodborne Pathog Dis*, 9 (11): 992-1001, 2012. DOI: 10.1089/fpd.2012.1175

11. Chen CM, Ke SC, Li CR, Wu YC, Chen TH, Lai CH, Wu XX, Wu LT: High diversity of antimicrobial resistance genes, class 1 Integrons, and genotypes of multidrug-resistant *Escherichia coli* in beef carcasses. *Microb Drug Resist*, 23 (7): 915-924, 2017. DOI: 10.1089/mdr.2016.0223

12. Guerra B, Junker E, Schroeter A, Malorny B, Lehmann S, Helmuth R: Phenotypic and genotypic characterization of antimicrobial resistance in German *Escherichia coli* isolates from cattle, swine and poultry. *J*

Antimicrob Chemother, 52 (3): 489-492, 2003. DOI: 10.1093/jac/dkg362

- 13. Kaesbohrer A, Schroeter A, Tenhagen BA, Alt K, Guerra B, Appel B:** Emerging antimicrobial resistance in commensal *Escherichia coli* with public health relevance. *Zoonoses Public Health*, 59 (Suppl 2): 158-165, 2012. DOI: 10.1111/j.1863-2378.2011.01451.x
- 14. Haenni M, Châtre P, Métayer V, Bour M, Signol E, Madec JY, Gay E:** Comparative prevalence and characterization of ESBL producing *Enterobacteriaceae* in dominant versus subdominant enteric flora in veal calves at slaughterhouse, France. *Vet Microbiol*, 171 (3-4): 321-327, 2014. DOI: 10.1016/j.vetmic.2014.02.023
- 15. Bosman AB, Wagenaar JA, Stegeman JA, Vernooij JC, Mevius DJ:** Antimicrobial resistance in commensal *Escherichia coli* in veal calves is associated with antimicrobial drug use. *Epidemiol Infect*, 142 (9): 1893-1904, 2014. DOI: 10.1017/S0950268813002665
- 16. Aguilar-Montes de Oca S, Talavera-Rojas M, Soriano-Vargas E, Barba-León J, Vazquez-Navarrete J:** Determination of extended spectrum β -lactamases/AmpC β -lactamases and plasmid-mediated quinolone resistance in *Escherichia coli* isolates obtained from bovine carcasses in Mexico. *Trop Anim Health Prod*, 47 (5): 975-981, 2015. DOI: 10.1007/s11250-015-0818-3
- 17. Kannan S, Ashokkumar K, Krishnamoorthy G, Dhasayan A, Marudhamuthu M:** Monitoring surfactant mediated defence of gastrointestinal *Proteus mirabilis* DMTMMK1 against pathogenic consortia of *Vibrio cholerae*. *RSC Adv*, 7 (34): 20969-20980, 2017. DOI: 10.1039/C7RA01934C
- 18. Clermont O, Bonacorsi S, Bingen E:** Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol*, 66 (10): 4555-4558, 2000. DOI: 10.1128/aem.66.10.4555-4558.2000
- 19. Clinical and Laboratory Standards Institute (CLSI):** Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement, *CLSI Document M100-S22*, Wayne, PA: Clinical and Laboratory Standart Institute; 2012.
- 20. Zhi C, Lv L, Yu LF, Doi Y, Liu JH:** Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis*, 16 (3): 292-293, 2016. DOI: 10.1016/S1473-3099(16)00063-3
- 21. Ng LK, Martin I, Alfa M, Mulvey M:** Multiplex PCR for the detection of tetracycline resistant genes. *Mol Cell Probes*, 15 (4): 209-215, 2001. DOI: 10.1006/mcpr.2001.0363
- 22. Sunde M, Norström M:** The prevalence of, associations between and conjugal transfer of antibiotic resistance genes in *Escherichia coli* isolated from Norwegian meat and meat products. *J Antimicrob Chemother*, 58 (4): 741-747, 2006. DOI: 10.1093/jac/dkl294
- 23. Sáenz Y, Briñas L, Domínguez E, Ruiz J, Zarazaga M, Vila J, Torres C:** Mechanisms of resistance in multiple-antibiotic-resistant *Escherichia coli* strains of human, animal, and food origins. *Antimicrob Agents Chemother*, 48 (10): 3996-4001, 2004. DOI: 10.1128/AAC.48.10.3996-4001.2004
- 24. Salaheen S, Cao H, Sonnier JL, Kim SW, Del Collo LP, Hovingh E, Karns JS, Haley BJ, Van Kessel JAS:** Diversity of extended-spectrum cephalosporin-resistant *Escherichia coli* in feces from calves and cows on pennsylvania dairy farms. *Foodborne Pathog Dis*, 16 (5): 368-370, 2019. DOI: 10.1089/fpd.2018.2579
- 25. Zhao S, Blickenstaff K, Bodeis-Jones S, Gaines SA, Tong E, McDermott PF:** Comparison of the prevalences and antimicrobial resistances of *Escherichia coli* isolates from different retail meats in the United States, 2002 to 2008. *Appl Environ Microbiol*, 78 (6): 1701-1707, 2012. DOI: 10.1128/AEM.07522-11
- 26. Carlos C, Pires MM, Stoppe NC, Hachich EM, Sato MI, Gomes TA, Amaral LA, Ottoboni LM:** *Escherichia coli* phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. *BMC Microbiol*, 10:161, 2010. DOI: 10.1186/1471-2180-10-161
- 27. Cocchi S, Grasselli E, Gutacker M, Benagli C, Convert M, Piffaretti JC:** Distribution and characterization of integrons in *Escherichia coli* strains of animal and human origin. *FEMS Immunol Med Microbiol*, 50 (1): 126-132, 2007. DOI: 10.1111/j.1574-695X.2007.00242.x
- 28. Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bingen E, Elion J, Denamur E:** The link between phylogeny and virulence in *Escherichia coli* extraintestinal infection. *Infect Immun*, 67 (2): 546-553, 1999.
- 29. Rodriguez-Siek KE, Giddings CW, Doetkott C, Johnson TJ, Fakhr MK, Nolan LK:** Comparison of *Escherichia coli* isolates implicated in human urinary tract infection and avian colibacillosis. *Microbiology*, 151 (6): 2097-2110, 2005. DOI: 10.1099/mic.0.27499-0
- 30. Asai T, Masani K, Sato C, Hiki M, Usui M, Baba K, Ozawa M, Harada K, Aoki H, Sawada T:** Phylogenetic groups and cephalosporin resistance genes of *Escherichia coli* from diseased food-producing animals in Japan. *Acta Vet Scand*, 53:52, 2011. DOI: 10.1186/1751-0147-53-52
- 31. Beceiro A, Tomás M, Bou G:** Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? *Clin Microbiol Rev*, 26 (2): 185-230, 2013. DOI: 10.1128/CMR.00059-12
- 32. Li XZ, Mehrotra M, Ghimire S, Adewoye L:** β -Lactam resistance and β -lactamases in bacteria of animal origin. *Vet Microbiol*, 121 (3-4): 197-214, 2007. DOI: 10.1016/j.vetmic.2007.01.015
- 33. Soufi L, Abbassi MS, Sáenz Y, Vinué L, Somalo S, Zarazaga M, Abbas A, Dbaya R, Khanfir L, Ben Hassen A, Hammami S, Torres:** Prevalence and diversity of integrons and associated resistance genes in *Escherichia coli* isolates from poultry meat in Tunisia. *Foodborne Pathog Dis*, 6 (9): 1067-1073, 2009. DOI: 10.1089/fpd.2009.0284
- 34. Blake DP, Humphry RW, Scott KP, Hillman K, Fenlon DR, Low JC:** Influence of tetracycline exposure on tetracycline resistance and the carriage of tetracycline resistance genes within commensal *Escherichia coli* populations. *J Appl Microbiol*, 94 (6): 1087-1097, 2003. DOI: 10.1046/j.1365-2672.2003.01937.x
- 35. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL:** Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*, 18 (3): 268-281, 2012. DOI: 10.1111/j.1469-0691.2011.03570.x
- 36. Wu RB, Alexander TW, Li JQ, Munns K, Sharma R, McAllister TA:** Prevalence and diversity of class 1 integrons and resistance genes in antimicrobial-resistant *Escherichia coli* originating from beef cattle administered subtherapeutic antibiotics. *J Appl Microbiol*, 111 (2): 511-523, 2011. DOI: 10.1111/j.1365-2672.2011.05066.x
- 37. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Butaye P, Goossens H:** Colistin resistance gene *mcr-1* harboured on a multidrug resistant plasmid. *Lancet Infect Dis*, 16 (3): 283-284, 2016. DOI: 10.1016/S1473-3099(16)00012-8
- 38. Haenni M, Poirel L, Kieffer N, Châtre P, Saras E, Métayer V, Dumoulin R, Nordmann P, Madec JY:** Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids. *Lancet Infect Dis*, 16 (3): 281-282, 2016. DOI: 10.1016/S1473-3099(16)00007-4
- 39. Van TTH, Chin J, Chapman T, Tran LT, Coloe PJ:** Safety of raw meat and shellfish in Vietnam: An analysis of *Escherichia coli* isolations for antibiotic resistance and virulence genes. *Int J Food Microbiol*, 124 (3): 217-223, 2008. DOI: 10.1016/j.ijfoodmicro.2008.03.029